Managing A Case of Heavily Pretreated Recurrent Ovarian Cancer
Managing A Case of Heavily Pretreated Recurrent Ovarian Cancer
Case: A 58-Year-Old Female With Heavily Pretreated Recurrent Ovarian Cancer
H & P
- 58-year-old female diagnosed in 2014 with stage IV ovarian cancer
- Pathology: high-grade serous carcinoma, epithelial ovarian cancer
- CA-125: 460 U/mL
- CT with contrast of the pelvis, abdomen, and chest revealed a 4-cm mass in the left ovary and peritoneal carcinomatosis
- Patient underwent suboptimal debulking surgery; residual disease 1.5 cm
- Received IV/IP carboplatin/paclitaxel (6 cycles); achieved complete remission
- 2 years later (2016) symptoms returned; CA 125, 255 U/mL; ECOG: 1
- Received carboplatin/paclitaxel (6 cycles) and bevacizumab; achieved good partial remission; CA 125, 45 U/mL; continued on bevacizumab maintenance
- 1.5-years following second-line therapy (2017), again presented with symptoms; CA 125, 550 U/mL; ECOG: 0
- Genetic testing;gBRCA1/2wild-type
- Received carboplatin/gemcitabine (6 cycles); CA 125, 46 U/mL; achieved complete remission
- Currently:
- CA 125, 620 U/mL
- CT shows several small masses in the lung left lower lobe (largest is 3 cm)
- ECOG: 0
Recent Videos
Related Content
KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer
September 14th 2024Article
Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.
Read More
